{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T12:17:40Z","timestamp":1768393060310,"version":"3.49.0"},"reference-count":26,"publisher":"Informa UK Limited","issue":"10","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2025,10,3]]},"DOI":"10.1080\/14712598.2025.2574011","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T06:34:23Z","timestamp":1760078063000},"page":"1113-1119","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Clinical and out-of-pocket cost outcomes after switching to biosimilar adalimumab-atto in patients with rheumatoid arthritis"],"prefix":"10.1080","volume":"25","author":[{"given":"Antony T-H","family":"Lin","sequence":"first","affiliation":[{"name":"Rheumatology Department, Southern California Permanente Medical Group","place":["Fontana, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3439-7410","authenticated-orcid":false,"given":"Fang","family":"Niu","sequence":"additional","affiliation":[{"name":"Pharmacy Outcomes Research Group, Kaiser Permanente National Pharmacy","place":["Downey, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0014-2431","authenticated-orcid":false,"given":"Rita L.","family":"Hui","sequence":"additional","affiliation":[{"name":"Pharmacy Outcomes Research Group, Kaiser Permanente National Pharmacy","place":["Oakland, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abbey","family":"Londa","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Kaiser Permanente Colorado","place":["Aurora, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8156-374X","authenticated-orcid":false,"given":"Catherine","family":"Pham","sequence":"additional","affiliation":[{"name":"Pharmacy Outcomes Research Group, Kaiser Permanente National Pharmacy","place":["Downey, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Teshima","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Kaiser Permanente Northern California","place":["South San Francisco, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6530-8415","authenticated-orcid":false,"given":"Thomas","family":"Delate","sequence":"additional","affiliation":[{"name":"Pharmacy Outcomes Research Group, Kaiser Permanente National Pharmacy","place":["Aurora, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"e_1_3_6_2_1","unstructured":"Amjevita\u2122 (adalimumab-atto) first biosimilar to Humira\u00ae now available in the United States. [cited 2025 Jun 6]. Available from: https:\/\/www.amgen.com\/newsroom\/press-releases\/2023\/01\/amjevita-adalimumabatto-first-biosimilar-to-humira-now-available-in-the-united-states"},{"key":"e_1_3_6_3_1","unstructured":"Amjevita\u2122 package insert. [cited 2025 Jun 6]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/761024lbl.pdf"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24596"},{"key":"e_1_3_6_5_1","unstructured":"FDA. Biosimilar overview for healthcare professionals. 2024 [cited 2025 Jun 6]. Available from: https:\/\/www.fda.gov\/drugs\/biosimilars\/overview-health-care-professionals"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-025-00727-z"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.638444"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1857-3"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00161-3"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0292231"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-022-00465-6"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-024-00459-6"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.37349\/emd.2025.100784"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.1025"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5253"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000182534.19832.83"},{"key":"e_1_3_6_17_1","unstructured":"Gardiner JC. Hypotheses for equivalence and non-inferiority with binary and survival outcomes. 2020 [cited 2025 Jun 6]. Available from: https:\/\/support.sas.com\/resources\/papers\/proceedings20\/4641-2020.pdf"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41257"},{"key":"e_1_3_6_19_1","unstructured":"Non-Inferiority Clinical Trials to Establish Effectiveness Guidance for Industry. U.S. Food and Drug Administration; 2016. [cited 2025 Jun 6]. Available from: https:\/\/www.fda.gov\/media\/78504\/download"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.1007"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15101"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210459"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/hec.4471"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2023.5429"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2763"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.37765\/ajmc.2022.89265"},{"issue":"5","key":"e_1_3_6_27_1","first-page":"e175","article-title":"Effects of integrated delivery system on cost and quality","volume":"19","author":"Hwang W","year":"2013","unstructured":"Hwang W, Chang J, Laclair M, et al. Effects of integrated delivery system on cost and quality. Am J Manag Care. 2013;19(5):e175\u201384.","journal-title":"Am J Manag Care"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2025.2574011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T07:35:20Z","timestamp":1768376120000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2025.2574011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,3]]}},"alternative-id":["10.1080\/14712598.2025.2574011"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2025.2574011","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-07-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}